Open AccessLow-dose, low-specific activity 131I-metaiodobenzyl guanidine therapy in metastatic pheochromocytoma/sympathetic paraganglioma: Single-center experience from Western India
Author(s) -
Rohit Barnabas,
Sanjeet Kumar Jaiswal,
Saba Samad Memon,
Vijaya Sarathi,
Gaurav Malhotra,
Priyanka Verma,
Virendra Patil,
Anurag Lila,
Nalini Shah,
Tushar Bandgar
Publication year - 2021
Publication title -
indian journal of endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.456
H-Index - 28
eISSN - 2230-9500
pISSN - 2230-8210
DOI - 10.4103/ijem.ijem_52_21
Subject(s) - medicine , radionuclide therapy , hormonal therapy , progressive disease , paraganglioma , oncology , gastroenterology , urology , disease , surgery , cancer , prostate cancer
Radionuclide therapy is a promising treatment modality in metastatic pheochromocytoma/paraganglioma (PPGL). There is scarce data on 131 I-metaiodobenzyl guanidine ( 131 I-MIBG) therapy from the Indian subcontinent. Hence, we aim to study the safety and effectiveness of low-dose, low-specific activity (LSA) 131 I-MIBG therapy in patients with symptomatic, metastatic PPGL.